Cellenkos Receives FDA Fast Track Designation for CK0803 in Amyotrophic Lateral Sclerosis (ALS)

RegulatoryCK0803Positive

AI Analysis

Summary

Cellenkos announced FDA Fast Track designation for CK0803, a cord blood-derived CNS-homing T-regulatory cell therapy for ALS, based on initial clinical data showing approximately 60% decrease in neurofilament light chain and 200% increase in plasma IL-10 levels.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

FDA Fast Track designation granted

Importance:7/10

Sentiment:

0.80

ALSFast TrackFDACK0803T-regulatory cellsCNS-homingneurofilament light chainplasma IL-10

Read the original article

Published by PR Newswire Biotech on August 25, 2026 12:06 PM

Read Original